睿知中国医院研究地图
候选清单

正在招募肺癌I期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

HS-IT101 Injection for Advanced NSCLC(FASTIL-Lung01)

ClinicalTrials.gov 上登记的一项肺癌开放试验。牵头方不是本站收录的医院;本站收录的 1 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 研究中心广东省人民医院Guangdong Provincial People's Hospital广州医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT07105176,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 6

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(6 项)收起清单
  1. 18 岁 至 75 岁;性别:不限

    登记记录的入选字段

  2. Patients with advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC) who have been confirmed by cytology or histology and have failed at least one line of standard first-line therapy. Patients with non-squamous NSCLC who are negative for EGFR/ALK/ROS1 driver mutations.

    入选标准第 2 条

  3. After sampling, there must be at least one measurable lesion that meets the RECIST 1.1 criteria definition, and this lesion has not undergone radiotherapy or other local treatments;

    入选标准第 4 条

    Prior to tumor sampling, adverse reactions induced by previous treatments have recovered to Grade 1 (5.0) or below according to the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0;

    入选标准第 9 条

    Individuals who have received systemic anti-tumor treatment within the 4 weeks prior to pre-treatment or those planning to participate in other interventional clinical trials during the study period;

    排除标准第 7 条

  4. ECOG score ≤ 1;

    入选标准第 5 条

  5. Within the 5 years prior to screening, diagnosed with concurrent other primary malignant tumors, excluding completely resected cutaneous basal cell carcinoma, cutaneous squamous cell carcinoma, and/or in situ carcinoma that has undergone radical excision;

    排除标准第 11 条

  6. Pregnant or lactating women;

    排除标准第 16 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义);化验:血常规、肝肾功能;影像与可测量病灶。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07105176,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Age: 18 to 75 years old;
  2. Patients with advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC) who have been confirmed by cytology or histology and have failed at least one line of standard first-line therapy. Patients with non-squamous NSCLC who are negative for EGFR/ALK/ROS1 driver mutations.
  3. There must be at least one tumor lesion that has not undergone radiation therapy or other local treatments within the past 28 days, which will be used to prepare autologous tumor-infiltrating lymphocytes, and it must meet the tissue sampling requirements.
  4. After sampling, there must be at least one measurable lesion that meets the RECIST 1.1 criteria definition, and this lesion has not undergone radiotherapy or other local treatments;
  5. ECOG score ≤ 1;
  6. The expected survival time is ≥ 3 months;
  7. During the screening period, the assessments showed adequate organ and bone marrow function,
  8. Echocardiography shows left ventricular ejection fraction (LVEF) ≥50%; no arrhythmias requiring treatment; QT interval corrected by the Fridericia method (QTcF) ≤470 ms; baseline blood oxygen saturation >91% in ambient air conditions;
  9. Prior to tumor sampling, adverse reactions induced by previous treatments have recovered to Grade 1 (5.0) or below according to the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0;
  10. From the signing of the informed consent form to one year after TIL cell infusion, agree to adopt effective non-pharmacological contraception measures;
  11. Those who fully understand this trial and voluntarily sign the informed consent form, and are able to comply with the visits and related procedures stipulated in the protocol.

排除标准:Exclusion Criteria:

  1. Patients who have previously experienced severe allergic reactions to drugs used during the research process;
  2. Presence of any uncontrolled clinical conditions, including but not limited to: poorly controlled hypertension; congestive heart failure;
  3. Within the past 6 months, the following conditions have occurred: deep vein thrombosis or pulmonary embolism; myocardial infarction; severe or unstable arrhythmia or angina; percutaneous coronary intervention, acute coronary syndrome, or coronary artery bypass grafting; cerebrovascular accident, transient ischemic attack, or cerebral embolism;
  4. Autoimmune diseases that are active and require systemic treatment during the study period;
  5. Organ transplantation or a history of hematopoietic stem cell transplantation;
  6. Within 4 weeks prior to tumor tissue sampling, the subject has used any immunosuppressive drugs, such as steroid medications, or the investigator determines that there are comorbid conditions requiring the use of immunosuppressive drugs during the trial. However, physiological doses of glucocorticoids are permitted, and intranasal or local use of steroid medications is allowed;
  7. Individuals who have received systemic anti-tumor treatment within the 4 weeks prior to pre-treatment or those planning to participate in other interventional clinical trials during the study period;
  8. Presence of acute or chronic infections, active infections requiring systemic treatment, or active tuberculosis infection;
  9. Individuals who have undergone major organ surgery or suffered significant trauma within the past 4 weeks, or who require elective surgery during the trial period;
  10. Patients with pre-selection surgical complications or delayed healing, and those judged by the researcher to be at increased risk for lymph node clearance pretreatment, adoptive TIL therapy, and IL-2 adjuvant therapy;
  11. Within the 5 years prior to screening, diagnosed with concurrent other primary malignant tumors, excluding completely resected cutaneous basal cell carcinoma, cutaneous squamous cell carcinoma, and/or in situ carcinoma that has undergone radical excision;
  12. Suffering from severe respiratory diseases;
  13. Patients with gastrointestinal bleeding requiring surgical treatment, or those with localized intestinal ischemia or perforation;
  14. Patients with known leptomeningeal metastasis; patients with other central nervous system metastases that are not effectively controlled by treatment or have not been treated;
  15. Has previously received similar cell therapy products;
  16. Pregnant or lactating women;
  17. Individuals with known mental illnesses, alcoholism, drug or substance abuse, or those deemed unsuitable by other researchers to participate in this trial.

引自 ClinicalTrials.gov, NCT07105176, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07105176,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT07105176